Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
151.65
+3.36 (2.27%)
Aug 12, 2026, 11:13 AM EDT - Market open
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Protagonist Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $165.31. The average 1-year stock price forecast is 9.01% higher than the current stock price, while the lowest is $112 (-26.15%) and the highest is $225 (+48.37%).
Price Target: $165.31 (+9.01%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 9 | 9 | 10 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Buy Maintains $145 → $170 | Buy | Maintains | $145 → $170 | +12.10% | Aug 10, 2026 |
| Wedbush | Wedbush | Buy Reiterates $173 | Buy | Reiterates | $173 | +14.08% | Aug 10, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Upgrades $186 | Buy | Upgrades | $186 | +22.65% | Aug 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $117 → $167 | Buy | Reiterates | $117 → $167 | +10.12% | Aug 10, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $155 | Buy | Maintains | $155 | +2.21% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
542.70M
from 46.02M
Increased by 1,079.38%
Revenue Next Year
190.81M
from 542.70M
Decreased by -64.84%
EPS This Year
4.81
from -2.05
EPS Next Year
-0.21
from 4.81
EPS and Forward PE are based on non-GAAP adjusted numbers.